Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 100,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 100,000 shares of the business's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $10.22, for a total transaction of $1,022,000.00. Following the transaction, the chief operating officer now directly owns 1,116,345 shares in the company, valued at approximately $11,409,045.90. The trade was a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Eric Venker also recently made the following trade(s):

• On Monday, March 24th, Eric Venker sold 434,478 shares of Roivant Sciences stock. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96.
• On Thursday, March 20th, Eric Venker sold 315,522 shares of Roivant Sciences stock. The stock was sold at an average price of $11.06, for a total value of $3,489,673.32.
• On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.65, for a total value of $1,065,000.00.
• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The shares were sold at an average price of $10.42, for a total value of $2,271,987.22.

Roivant Sciences Stock Up 3.8 %

Shares of ROIV traded up $0.38 during mid-day trading on Tuesday, reaching $10.42. 6,333,426 shares of the stock traded hands, compared to its average volume of 5,417,338. The stock has a fifty day simple moving average of $10.32 and a 200 day simple moving average of $11.16. The firm has a market cap of $7.44 billion, a price-to-earnings ratio of -69.46 and a beta of 1.25. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, equities research analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Roivant Sciences

Several large investors have recently made changes to their positions in the company. Barclays PLC lifted its holdings in Roivant Sciences by 19.7% in the 3rd quarter. Barclays PLC now owns 459,521 shares of the company's stock valued at $5,302,000 after acquiring an additional 75,609 shares during the last quarter. Virtu Financial LLC purchased a new position in Roivant Sciences during the third quarter valued at approximately $207,000. Te Ahumairangi Investment Management Ltd boosted its position in Roivant Sciences by 19.9% during the third quarter. Te Ahumairangi Investment Management Ltd now owns 201,612 shares of the company's stock valued at $2,313,000 after purchasing an additional 33,467 shares during the last quarter. Tyro Capital Management LLC increased its holdings in Roivant Sciences by 0.6% in the third quarter. Tyro Capital Management LLC now owns 1,754,976 shares of the company's stock worth $20,252,000 after buying an additional 10,649 shares during the last quarter. Finally, Retirement Systems of Alabama increased its stake in shares of Roivant Sciences by 26.9% during the 3rd quarter. Retirement Systems of Alabama now owns 530,022 shares of the company's stock worth $6,116,000 after purchasing an additional 112,286 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Monday.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.